Summary
Global Markets Direct’s, ‘Amgen Inc. - Product Pipeline Review - 2016’, provides an overview of the Amgen Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Amgen Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Amgen Inc.
- The report provides overview of Amgen Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Amgen Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Amgen Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Amgen Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Amgen Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Amgen Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Amgen Inc. Snapshot 7
Amgen Inc. Overview 7
Key Information 7
Key Facts 7
Amgen Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Amgen Inc. - Pipeline Review 16
Pipeline Products by Stage of Development 16
Pipeline Products - Monotherapy 17
Pipeline Products - Partnered Products 18
Pipeline Products - Out-Licensed Products 20
Amgen Inc. - Pipeline Products Glance 23
Amgen Inc. - Late Stage Pipeline Products 23
Amgen Inc. - Clinical Stage Pipeline Products 26
Amgen Inc. - Early Stage Pipeline Products 29
Amgen Inc. - Drug Profiles 33
adalimumab biosimilar 33
blinatumomab 34
darbepoetin alfa 37
denosumab 39
etanercept 42
etelcalcetide hydrochloride 44
romiplostim 46
AMG-334 48
bevacizumab biosimilar 49
evolocumab 50
fulranumab 53
panitumumab 56
rituximab biosimilar 59
romosozumab 60
trastuzumab biosimilar 62
trebananib 63
abrilumab 66
AMG-319 67
AMG-337 69
AMG-557 70
AMG-714 72
AMG-899 74
ganitumab 75
omecamtiv mecarbil MR 78
rilotumumab 81
tezepelumab 83
AMG-232 85
talimogene laherparepvec 86
AMG-172 89
AMG-208 90
AMG-211 91
AMG-224 93
AMG-228 94
AMG-282 95
AMG-301 96
AMG-330 97
AMG-357 98
AMG-581 99
AMG-592 100
AMG-595 101
AMG-780 103
AMG-811 104
AMG-820 105
AMG-876 106
AMG-900 107
AMG-XXX 109
infliximab biosimilar 110
pasotuxizumab 111
solitomab 113
AM-1638 114
AM-3189 115
AM-6226 116
AM-7209 117
AM-8553 118
AM-9514 119
AMG-0696 120
AMG-161 121
AMG-1694 122
AMG-176 123
AMG-3969 124
AMG-511 125
AMG-570 126
AMG-8718 127
AMG-986 128
Biosimilar 1 for Undisclosed Indication 129
Biosimilar 2 for Undisclosed Indication 130
Biosimilar 3 for Undisclosed Indication 131
Calcimimetic-18 132
cetuximab biosimilar 133
Drug for Atherosclerosis 134
Drugs to Inhibit FGF23 for Bone Disorders 135
Morpholinone-27 136
Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases 137
Recombinant Protein to Agonize FGFR for Type 2 Diabetes 138
Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes 139
Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase for Obesity, Dyslipidemia and Type 2 Diabetes 140
Small Molecule to Agonize GPR119 for Undisclosed Indication 141
Small Molecule to Agonize GPR119 Receptor for Undisclosed Indication 142
Small Molecule to Agonize GPR142 for Type 2 Diabetes 143
Small Molecule to Antagonize EP2 Receptor for Alzheimer Disease 144
Small Molecule to Inhibit BACE1 for Alzheimer's Disease 145
Small Molecule to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis 146
Small Molecule to Inhibit PI3K/mTOR for Cancer 147
Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease 148
Small Molecules to Inhibit BACE1 for Alzheimer Disease 149
Small Molecules to Inhibit PDE10A for Neurological Diseases 150
Small Molecules to Inhibit PI3K Delta for Inflammation 151
XmAb-13243 152
XmAb-13551 153
AA-71 154
Drugs for Inflammatory Bowel Disease 155
Monoclonal Antibodies for Cancer and Inflammation 156
Morpholinone-10 157
Morpholinone-16 158
Small Molecules to Inhibit CDC7 kinase for Cancer 159
Small Molecules to Inhibit IRAK-4 for Inflammation 160
Small Molecules to Inhibit NIK for Multiple Myeloma 161
Small Molecules to Inhibit Tankyrase for Cancer 162
Amgen Inc. - Pipeline Analysis 163
Amgen Inc. - Pipeline Products by Target 163
Amgen Inc. - Pipeline Products by Route of Administration 168
Amgen Inc. - Pipeline Products by Molecule Type 169
Amgen Inc. - Pipeline Products by Mechanism of Action 170
Amgen Inc. - Recent Pipeline Updates 174
Amgen Inc. - Dormant Projects 225
Amgen Inc. - Discontinued Pipeline Products 229
Discontinued Pipeline Product Profiles 230
Amgen Inc. - Company Statement 235
Amgen Inc. - Locations And Subsidiaries 237
Head Office 237
Other Locations & Subsidiaries 237
Amgen Inc. - Key Manufacturing Facilities 242
Appendix 243
Methodology 243
Coverage 243
Secondary Research 243
Primary Research 243
Expert Panel Validation 243
Contact Us 243
Disclaimer 244
List of Tables
Amgen Inc., Key Information 14
Amgen Inc., Key Facts 14
Amgen Inc. - Pipeline by Indication, 2016 16
Amgen Inc. - Pipeline by Stage of Development, 2016 23
Amgen Inc. - Monotherapy Products in Pipeline, 2016 24
Amgen Inc. - Partnered Products in Pipeline, 2016 25
Amgen Inc. - Partnered Products/ Combination Treatment Modalities, 2016 26
Amgen Inc. - Out-Licensed Products in Pipeline, 2016 27
Amgen Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 28
Amgen Inc. - Pre-Registration, 2016 30
Amgen Inc. - Filing rejected/Withdrawn, 2016 31
Amgen Inc. - Phase III, 2016 32
Amgen Inc. - Phase II, 2016 33
Amgen Inc. - Phase I, 2016 34
Amgen Inc. - Preclinical, 2016 36
Amgen Inc. - Discovery, 2016 39
Amgen Inc. - Pipeline by Target, 2016 170
Amgen Inc. - Pipeline by Route of Administration, 2016 175
Amgen Inc. - Pipeline by Molecule Type, 2016 176
Amgen Inc. - Pipeline Products by Mechanism of Action, 2016 177
Amgen Inc. - Recent Pipeline Updates, 2016 181
Amgen Inc. - Dormant Developmental Projects,2016 232
Amgen Inc. - Discontinued Pipeline Products, 2016 236
Amgen Inc., Other Locations 244
Amgen Inc., Subsidiaries 246
Amgen Inc., Key Manufacturing Facilities 249
List of Figures
Amgen Inc. - Pipeline by Top 10 Indication, 2016 16
Amgen Inc. - Pipeline by Stage of Development, 2016 23
Amgen Inc. - Monotherapy Products in Pipeline, 2016 24
Amgen Inc. - Partnered Products in Pipeline, 2016 25
Amgen Inc. - Out-Licensed Products in Pipeline, 2016 27
Amgen Inc. - Pipeline by Top 10 Target, 2016 170
Amgen Inc. - Pipeline by Route of Administration, 2016 175
Amgen Inc. - Pipeline by Molecule Type, 2016 176
Amgen Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 177
